CD8A and T-cell non-Hodgkin lymphoma: The second contingent was peripheral T-cell lymphoma in 72.7% (8/11), T-cell prolymphocytic leukemia in 18.2% (2/11), and cytotoxic CD8+ T-cell lymphoma in 9.1% (1/11) of cases.